NCT02596555终止4 期
Safety and Efficacy of Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for the Treatment of Acute Intermediate-Risk Pulmonary Embolism
Prof. Stavros Konstantinides, MD1 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2016年1月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 发起方
- 入组人数
- 400
- 试验地点
- 1
- 主要终点
- Occurrence of symptomatic venous thromboembolism (VTE) or pulmonary embolism (PE) related death (yes/no)
研究概览
简要总结
This prospective, multicenter, multinational, phase IV, interventional single-armed (management) trial will focus on the safety, efficacy and cost-effectiveness of a new oral anticoagulant in the treatment of patients with acute intermediate-risk PE based on validated imaging (echocardiographic or CT angiographic) and laboratory biomarker (circulating levels of cardiac troponins and natriuretic peptides) parameters and their combinations.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years
- •Objectively confirmed diagnosis of acute PE by multidetector CT angiography, ventilation/perfusion lung scan, or selective invasive pulmonary angiography, according to established diagnostic criteria, with or without symptomatic deep vein thrombosis
- •Absence of hemodynamic collapse, or decompensation, at presentation; Hemodynamic collapse or decompensation
- •Intermediate-risk category of PE severity indicated by a positive (score ≥1) simplified pulmonary embolism severity index (sPESI), in combination with the presence of at least one of the following criteria at presentation:
- •At least one sign of RV pressure overload/dysfunction on CT angiography or echocardiography
- •Signs of myocardial injury as indicated by elevated troponin levels
- •Signs of (RV) failure as indicated by NT-proBNP levels >600 pg/ml at baseline.
- •Ability of the subject to understand the character and individual consequences of the clinical trial; signed and dated informed consent of the subject available before the start of any specific trial procedures
排除标准
- •Pregnancy (a negative serum or urine pregnancy test should be available for women of child-bearing potential before study inclusion) or lactation
- •Women of childbearing potential who do not practice a medically accepted highly effective contraception during the trial and one month beyond
- •History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product
- •Participation in another clinical trial during the present clinical trial or within the last three months
- •Medical or psychological condition that would not permit completion of the trial or signing of informed consent
- •Use of a fibrinolytic agent, surgical thrombectomy, interventional (catheter-directed) thrombus aspiration or lysis, or use of a cava filter to treat the index episode of PE
- •Treatment with any therapeutically dosed anticoagulant for more than 48 hours prior to enrolment
- •Need for long-term treatment with a low molecular weight heparin, vitamin K antagonists or NOAC, for an indication other than the index PE episode, or for antiplatelet agents except acetylsalicylic acid at a dosage ≤100 mg/day;
- •Active bleeding or known significant bleeding risk (e.g., gastrointestinal ulcer, malignant neoplasms, injuries or recent surgeries of the brain, spinal cord or eyes, recent intracranial bleedings, known or suspected esophagus varices, aneurysms or intraspinal or intracranial vascular abnormalities)
- •Artificial heart valves requiring treatment with an anticoagulant
- •Renal insufficiency with estimated creatinine clearance <30 ml/min/1.73m2
- •Chronic liver disease with aminotransferase levels two times or more above the local upper limit of normal range
- •Concomitant administration of strong inhibitors of P-glycoprotein like ketoconazole, cyclosporin, itraconazole or dronedarone
- •Unwillingness or inability to adhere to treatment or to the follow-up visits
- •Life expectancy less than 6 months
研究组 & 干预措施
Dabigatran treatment
Experimental
Low molecular weight heparin for 72 hours followed by 6 months of dabigatran
干预措施: Dabigatran (Drug)
结局指标
主要结局
Occurrence of symptomatic venous thromboembolism (VTE) or pulmonary embolism (PE) related death (yes/no)
时间窗: 6 months
次要结局
- Death from any cause(30 days)
- Pulmonary embolism (PE) related death, or PE-related or hemodynamic collapse or decompensation(30 days)
- Overall duration of hospital stay(6 months)
- Major bleeding(6 months)
- Clinically relevant bleeding(6 months)
- Serious adverse events (SAE)(72 hours, 30 days, 6 months)
- Recovery of right ventricle (RV) function(6±1 days or upon discharge (whichever comes first), 6 months)
- Temporal pattern of changes in NT-proBNP (N-terminal prohormone of brain natriuretic peptide) levels(6±1 days or upon discharge (whichever comes first), 6 months)
研究者
Prof. Stavros Konstantinides, MD
Medical Director of Center for Thrombosis and Hemostasis, University Medical Center Mainz
Johannes Gutenberg University Mainz
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary SyndromeMyocardial InfarctionAcute Coronary SyndromeMyocardial IschemiaUnstable AnginaNCT03363035Second Xiangya Hospital of Central South University2,055
进行中（未招募）
1 期
Safety and Efficacy of Heparin for 72 Hours Followed by Dabigatran for the Treatment of Acute Pulmonary Embolism.EUCTR2015-001830-12-ATniversity Medical Center of the Johannes Gutenberg University Mainz700
进行中（未招募）
1 期
Safety and Efficacy of Heparin for 72 Hours Followed by Dabigatran for the Treatment of Acute Pulmonary Embolism.Acute Intermediate-Risk Pulmonary EmbolismMedDRA version: 19.0Level: HLTClassification code 10037379Term: Pulmonary embolism and thrombosisSystem Organ Class: 100000004866EUCTR2015-001830-12-NLniversity Medical Center of the Johannes Gutenberg University Mainz700
进行中（未招募）
1 期
Safety and Efficacy of Heparin for 72 Hours Followed by Dabigatran for the Treatment of Acute Pulmonary Embolism.Acute Intermediate-Risk Pulmonary EmbolismMedDRA version: 20.0Level: HLTClassification code 10037379Term: Pulmonary embolism and thrombosisSystem Organ Class: 100000004866EUCTR2015-001830-12-ITIVERSITY MEDICAL SCHOOL OF THE JOHANNES GUTENBERG UNIVERSITY MAINZ530
进行中（未招募）
1 期
Safety and Efficacy of Heparin for 72 Hours Followed by Dabigatran for the Treatment of Acute Pulmonary Embolism.acute intermediate-risk of pulmonary embolismMedDRA version: 20.0Level: LLTClassification code 10014521Term: Embolism pulmonarySystem Organ Class: 100000015973EUCTR2015-001830-12-FRJOHANNES GUTENBERG UNIVERSITY700